The First Pulmonary Hypertension Registry in the United Arab Emirates (UAEPH): Clinical Characteristics, Hemodynamic Parameters with Focus on Treatment and Outcomes for Patients with Group 1-PH

Khaled Saleh, Naureen Khan, Kelly Dougherty, Govinda Bodi, Miriam Michalickova, Samiuddin Mohammed, Theodora Kerenidi, Ziad G. Sadik, Jihad Mallat, Samar Farha, Hani SabbourJournal of Clinical Medicine 2023 · DOI

TL;DR

This paper presents the first registry of Group 1 Pulmonary Hypertension (PH) patients in the United Arab Emirates (UAE), offering crucial insights into their clinical characteristics, treatment, and outcomes. The findings reveal a younger cohort with a higher prevalence of congenital heart disease compared to Western registries, highlighting the need for tailored approaches and improved medication access in the region.

What Problem Does This Paper Address?

Pulmonary Hypertension (PH) is a serious condition characterized by elevated pressure in the pulmonary arteries, leading to right heart failure and potentially death. It's classified into five groups based on underlying causes. Group 1-PH, specifically Pulmonary Arterial Hypertension (PAH), is a rare and progressive form. While numerous PH registries exist globally, providing valuable data on patient demographics, disease progression, and treatment efficacy, there was a significant gap in understanding this patient population within the United Arab Emirates (UAE). This study aims to fill that gap by establishing the first comprehensive registry for Group 1-PH patients in the UAE, enabling a better understanding of their unique characteristics and informing future clinical practice and research in the region.

Methods

This was a retrospective, single-center study conducted at Cleveland Clinic Abu Dhabi. Researchers analyzed data from adult patients (age ≥ 14) who underwent right heart catheterization for PH evaluation between January 2015 and December 2021. The study included patients with confirmed PH diagnoses. Data collected included demographics, comorbidities, clinical characteristics (e.g., 6-minute walk test, NT-proBNP), hemodynamic parameters from right heart catheterization, and treatment strategies. The updated classification of PAH from the 2018 6th World Symposium of Pulmonary Arterial Hypertension was used. Statistical analysis involved descriptive statistics, comparative tests (ANOVA, Kruskal-Wallis, Chi-squared, Fisher's exact), and survival analysis using the Kaplan-Meier method.

Datasets

The study utilized data from a retrospective cohort of 164 patients diagnosed with pulmonary hypertension at a single tertiary referral center in Abu Dhabi, UAE, between January 2015 and December 2021. Of these, 83 patients were diagnosed with Group 1-PH. No new benchmarks were introduced; the study focused on characterizing an existing patient population within a specific geographical region.

Key Insights and Ideas

  • Unique Demographics: The UAEPH cohort is notably younger and has a higher proportion of patients with congenital heart disease (CHD) compared to Western registries. This suggests potential differences in the underlying causes and presentation of PH in this population.
  • Treatment Escalation: The study observed a common trend of escalating vasodilator therapy from monotherapy to dual and then triple combinations over time, reflecting current treatment guidelines.
  • Medication Access as a Barrier: While treatment strategies are evolving, the paper hints at challenges with medication access and adherence, particularly for expensive therapies like parenteral prostanoids, which could impact outcomes.
  • Importance of Early Diagnosis: The finding that CTD subgroup patients might be diagnosed later than their idiopathic counterparts, despite CTD being a known risk factor for PH, underscores the importance of rheumatologists' awareness and timely referral.
  • Potential for Improvement: The recent improvement in medication access through patient-support programs in the UAE offers a promising avenue for enhancing clinical outcomes in the future.

Key Results

  • A total of 164 patients were diagnosed with PH, with 83 (50.6%) classified as Group 1-PH.
  • Within Group 1-PH, the primary subgroups were idiopathic (30%), connective tissue disease (CTD) (33%), and congenital heart disease (CHD) (31%).
  • The median follow-up period was 55.6 months.
  • The 1-, 3-, and 5-year cumulative survival probabilities for Group 1-PH were 86%, 69%, and 69%, respectively.
  • The CHD subgroup showed statistically significant improvement in the 6-minute walk test (6-MWT) and right ventricular systolic pressure (RVSP) over the follow-up period, unlike the idiopathic and CTD subgroups.
  • Mortality rates were comparable to other major international registries.

Limitations and Future Work

The authors acknowledge several limitations:

  • Retrospective Nature: The study design inherently limits the ability to establish causality and may be subject to data completeness issues.
  • Small Cohort Size: While the first registry of its kind in the UAE, the number of patients is relatively small, potentially limiting generalizability.
  • Limited Repeat RHC: Invasive hemodynamic assessments were not routinely performed at follow-up, meaning that changes in hemodynamics over time were not comprehensively captured.
  • Data on Medication Adherence: Detailed data on patient adherence to medication was limited.
  • Impact of COVID-19: The study period overlapped with the COVID-19 pandemic, which may have affected patient management, treatment adherence, and outcomes.
  • Expatriate Population: The high proportion of expatriate patients might limit the generalizability of findings to the entire UAE population.

Future work should focus on adopting updated guideline recommendations, improving medication availability and adherence (especially for parenteral prostanoids), and potentially expanding the registry to include more centers to increase sample size and generalizability. Further research into the specific factors contributing to the higher prevalence of CHD in the UAE PH population would also be valuable.

Summary updated

Abstract

This is the first registry of Group 1-PH from a single tertiary referral center in the UAE. Our cohort was younger with a higher percentage of patients with congenital heart disease compared to cohorts from Western countries but similar to registries from other Asian countries. Mortality is comparable to other major registries. Adopting the new guideline recommendations and improving the availability and adherence to medications are likely to play a significant role in improving outcomes in the future.
BibTeX
@article{saleh2023first,
  author = {Khaled Saleh and Naureen Khan and Kelly Dougherty and Govinda Bodi and Miriam Michalickova and Samiuddin Mohammed and Theodora Kerenidi and Ziad G. Sadik and Jihad Mallat and Samar Farha and Hani Sabbour},
  title = {{The First Pulmonary Hypertension Registry in the United Arab Emirates (UAEPH): Clinical Characteristics, Hemodynamic Parameters with Focus on Treatment and Outcomes for Patients with Group 1-PH}},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  doi = {10.3390/jcm12051996},
}
Figure